Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level685 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,087 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00660101 | Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer | unknown | Phase 1 / Phase 2 | 34 | AVAX TechnologiesINDUSTRY | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00059787 | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Dec 1, 2015 | clinicaltrials |
| NCT00313612 |
| Oxaliplatin and Topotecan in Advance Ovarian Cancer |
| terminated |
| Phase 2 |
| 39 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Nov 27, 2015 |
| clinicaltrials |
| NCT00024258 | Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors | completed | Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2015 | clinicaltrials |
| NCT01091259 | Irinotecan and Bevacizumab for Recurrent Ovarian Cancer | completed | Phase 2 | 29 | NYU Langone HealthOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT00275028 | AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Nov 9, 2015 | clinicaltrials |
| NCT00453310 | Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment | completed | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 27, 2015 | clinicaltrials |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 79 | Otsuka Novel Products GmbHINDUSTRY | 1 | Oct 20, 2015 | clinicaltrials |
| NCT00758732 | Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma | terminated | Phase 2 | 34 | Hellenic Oncology Research GroupOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT00318370 | Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy | completed | Phase 2 | 58 | MorphotekINDUSTRY | 2 | Sep 9, 2015 | clinicaltrials |
| NCT01296035 | Panitumumab and Gemcitabine in Relapsed Ovarian Cancer(PanGem) | terminated | Phase 2 | 8 | Women and Infants Hospital of Rhode IslandOTHER | 1 | Aug 25, 2015 | clinicaltrials |
| NCT00945139 | Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA) | completed | Phase 2 | 46 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 31, 2015 | clinicaltrials |
| NCT00421889 | A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | completed | Phase 1 / Phase 2 | 80 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00072267 | UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | — | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT01175772 | Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy | terminated | Phase 2 | 6 | HaEmek Medical Center, IsraelOTHER | 1 | Jun 23, 2015 | clinicaltrials |
| NCT01880996 | Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Sheba Medical CenterOTHER_GOV | 1 | Jun 11, 2015 | clinicaltrials |
| NCT00096993 | A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 131 | Genentech, Inc.INDUSTRY | 1 | Jun 10, 2015 | clinicaltrials |
| NCT01690598 | Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | completed | Phase 1 / Phase 2 | 22 | Vejle HospitalOTHER | 1 | Jun 10, 2015 | clinicaltrials |
| NCT01200797 | SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin | terminated | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT02188550 | Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer | unknown | Phase 2 | 20 | Sinai Hospital of BaltimoreOTHER | 1 | May 19, 2015 | clinicaltrials |
| NCT00343044 | Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers | completed | Phase 2 | 40 | Benaroya Research InstituteOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT00072566 | Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | May 12, 2015 | clinicaltrials |
| NCT02435186 | p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | unknown | Phase 2 | 100 | Shenzhen SiBiono GeneTech Co.,LtdINDUSTRY | 1 | May 6, 2015 | clinicaltrials |
| NCT01196741 | Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer(SaPPrOC) | completed | Phase 2 / Phase 3 | 107 | University College, LondonOTHER | 1 | May 5, 2015 | clinicaltrials |
| NCT00039585 | Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00267696 | Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 2 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00003880 | Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer | terminated | Phase 2 / Phase 3 | 132 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 16, 2015 | clinicaltrials |
| NCT00345540 | Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer | completed | Phase 2 | 15 | Cellectar Biosciences, Inc.INDUSTRY | 1 | Mar 10, 2015 | clinicaltrials |
| NCT00442598 | Safety and Efficacy Study of Glufosfamide in Ovarian Cancer | terminated | Phase 2 | 17 | Eleison Pharmaceuticals LLC.INDUSTRY | 1 | Mar 10, 2015 | clinicaltrials |
| NCT00090610 | Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer | completed | Phase 2 | 150 | Duke UniversityOTHER | 1 | Feb 25, 2015 | clinicaltrials |
| NCT01047891 | Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer(TRIAS 2009) | completed | Phase 2 | 174 | JSehouliOTHER | 1 | Feb 18, 2015 | clinicaltrials |
| NCT01196559 | Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer | completed | Phase 2 | 44 | The Catholic University of KoreaOTHER | 1 | Feb 18, 2015 | clinicaltrials |
| NCT01815528 | Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer | completed | Phase 2 | 2 | JSehouliOTHER | 1 | Feb 18, 2015 | clinicaltrials |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | terminated | Phase 1 / Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 5, 2015 | clinicaltrials |
| NCT00388037 | Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 27, 2015 | clinicaltrials |
| NCT00312650 | Doxil and Gemcitabine in Recurrent Ovarian Cancer | terminated | Phase 2 | 24 | Women and Infants Hospital of Rhode IslandOTHER | 1 | Jan 12, 2015 | clinicaltrials |
| NCT00507741 | Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02) | completed | Phase 2 | 49 | EndocyteINDUSTRY | 0 | Jan 7, 2015 | clinicaltrials |
| NCT00722592 | Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)(PRECEDENT) | completed | Phase 2 | 162 | EndocyteINDUSTRY | 0 | Jan 7, 2015 | clinicaltrials |
| NCT00390611 | Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer | completed | Phase 2 | 85 | SCRI Development Innovations, LLCOTHER | 1 | Dec 22, 2014 | clinicaltrials |
| NCT01747239 | Cabazitaxel in Platinum Refractory Ovarian Cancer | terminated | Phase 2 | 4 | Vejle HospitalOTHER | 1 | Dec 4, 2014 | clinicaltrials |
| NCT02004093 | A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer | completed | Phase 2 | 149 | Hoffmann-La RocheINDUSTRY | 9 | Dec 4, 2014 | clinicaltrials |
| NCT00751205 | Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC) | completed | Phase 2 | 150 | BayerINDUSTRY | 6 | Oct 28, 2014 | clinicaltrials |
| NCT00928642 | Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 8 | Henry M. Jackson Foundation for the Advancement of Military MedicineOTHER | 1 | Oct 21, 2014 | clinicaltrials |
| NCT00868192 | Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | completed | Phase 2 | 38 | Washington University School of MedicineOTHER | 1 | Oct 20, 2014 | clinicaltrials |
| NCT01481701 | A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma | completed | Phase 2 | 90 | Jules Bordet InstituteOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT01834469 | Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients(OV-AP-ICG-IV) | completed | Phase 1 / Phase 2 | 10 | Jules Bordet InstituteOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT01149434 | Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers | terminated | Phase 1 / Phase 2 | 19 | University of UtahOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00477386 | Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 28 | Indiana UniversityOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT02017678 | Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin | withdrawn | Phase 2 | 0 | Andrea McCartOTHER | 1 | Sep 17, 2014 | clinicaltrials |
| NCT00410462 | Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma | unknown | Phase 2 | 118 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Aug 8, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Dec 3, 2015source: clinicaltrials